July 1, 2025 5:18pm

From the seemingly overbought to the oversold to a positive close

As I wrote Monday, “Love the highs, almost time to cry as Q2 comes to an end and earnings season evolves; unless you do or don’t say bye to some holdings”

I say what others won’t, so you can do what others can’t!

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets.

I put hours of effort to create reporting, while leveraging my 40 years of operating. investigative and research experiences to analyze the key sector-moving events and distill that into a cogent outlook.

 

Tuesday’s RegMed Investors’ (RMi) pre-open: Are we ready for the 2nd half and resumption of the earnings cycle … https://www.regmedinvestors.com/articles/13981

Monday night’s RegMed Investors (RMi) Closing Bell: the sword hung by a single horsehair, implying an ever-present peril facing share pricing … https://www.regmedinvestors.com/articles/13980

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Tuesday: The Dow closed UP +400.17 points or +0.91%, the S&P closed DOWN -6.94 points or -0.11% while the Nasdaq closed DOWN -165.85 points or -0.82%

  • Theme of the session, rotating to start new Q3

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  • The ISM manufacturing index came in at 49.0 for June, above the Dow Jones consensus of 48.6. A reading below 50 indicates contraction.
  • Fresh data Tuesday showed job openings rose more than expected in May. The hiring and quits rates remain near decade lows, reflecting what economists have described as a labor market in "stasis." <Yahoo Finance>
  • Trade deal frameworks with China and the UK are reportedly now on the table ahead of Trump's self-imposed July 9 deadline. This has led investors to price in a "Goldilocks scenario" for stocks, with sustained earnings growth, little effects from tariffs, and rate cuts from the Fed.

Tuesday’s advance/decline line opened negative with 10 incliners, 22 decliners and 3 flats ending with a positive close of 21 incliners, 11 decliners and 3 flats      

Metrics:  Monday, the IBB was up +1.12%, the XBI was up +0.16% while the VIX was up +0.10points or +0.60% at 16.83

 

Q3 – 7/1/25 -  1 positive close

Q2/25:

  • June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Tuesday Closing UP (10 of 21) 

  • Mesoblast (MESO +$1.23),
  • Moderna (MRNA +$1.10 after Monday’s +$0.43).
  • Lenz Therapeutics (LENZ +$0.74 after Monday’s -$0.87),
  • Beam Therapeutics (BEAM +$0.52 after Monday’s +$0.21),
  • Intellia Therapeutics (NTLA +$0.50 after Monday’s -$0.18),
  • Ionis Pharmaceuticals (IONS +$0.43 after Monday’s -$0.29).
  • Agenus (AGEN +$0.27 after Monday’s -$0.19),
  • Prime Medicine (PRME +$0.26),
  • Blueprint Medicine (BPMC +$0.16),
  • Adverum Biotechnologies (ADVM +$0.13 after Monday’s -$0.17),

Flat (3)

  • bluebird bio (BLUE) P/E acquired
  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Monday’s +$0.10 with 8100 shares traded - ??)
  • Homology Medicine (FIXX)

Tuesday’s Closing DOWN (11 of 11): 

  • Alnylam Pharmaceuticals (ALNY -$4.03 after Monday’s +$3.26),
  • Vericel (VCEL -$0.95 after Monday’s +$0.82),
  • Solid Biosciences (SLDB -$0.27 after Monday’s +$0.15)
  • CRISPR Therapeutics (CRSP -$0.13 after Monday’s +$1.15),
  • Ultragenyx Pharmaceuticals (RARE -$0.10 after Monday’s -$0.16),
  • Sage Therapeutics (SAGE -$0.04 after Monday’s -$0.03),
  • Compass Therapeutics (CMPX -$0.02),
  • Brainstorm Cell Therapeutics (BCLI -$0.01),
  • Caribou Biosciences (CRBU -$0.01),
  • Sangamo Therapeutics (SGMO -$0.0051),
  • Generation Bio (GBIO -$0.0001),

 

The BOTTOM LINE:  Cell and gene therapy sector equities made an impressive comeback mid-day after suffering a steep decline at the open.

  • The major averages have since made a sharp recovery, with the broad market index closing Q2 with a 10.6% gain and the Nasdaq up nearly 18% in the period.

The last session of June Monday … closed positive end to Q2/25

  • Last week <6/23 to 6/27> opens with a barely Monday negative close followed by a Tuesday positive close and a barely negative close on Wednesday and Thursday… followed by another down turn in negative territory on Friday
  • The previous week, 6/16 – 6/20 started with a Monday positive close … followed by Tuesday’s negative close … and a Wednesday’s positive close, Thursday’s market holiday and Friday’s negative close.
  • The week of 6/9 – 6/13; Friday, the cell and gene therapy sector stayed in negative territory following Thursday's trading session ended with a negative territory, after May's Producer Price Index (PPI) report following Wednesday's negative close after May's Consumer Price Index (CPI) report post Monday’s neutral close.
  • The cell and gene therapy sector popped Friday after Thursday’s reverses on Thursday from a negative open with a barely positive close after Wednesday’s positive close – although slipping
  • Following upsides on Tuesday and Monday) after its “napping and waking” in the May share pricing doldrums initiated by a sweetener of BPMC getting an acquired by BMY, MRNA regulatory approval and BNTX’s partnership with BMY.

The “Big Beautiful Bill:

  • Senate lawmakers voted 50-50, with Vice President JD Vance breaking the tie, to pass Trump's signature tax and spending bill, racing to meet the president's desired July 4 deadline. The bill now goes back to the House, which will vote on the Senate's changes.

Interesting … Sam Stoval Sam Stovall, chief investment strategist at CFRA Research speaks/writes:

  • “No one could fault an investor if at one point during the first half of 2025 they shouted, ‘Stop the world, I want to get off,’”. “Indeed, 33% of all trading days experienced volatility of 1% or more, versus the 10-year average of 25%, and almost reaching 50% of all days from the peak on February 19 through the end of the near-19% correction on April 8.”
  • The S&P 500 is due for further gains now that it’s surpassed that challenge, Stovall said. The strategist said the broad market index could climb another 6% to 10%, based on similar scenarios across market history, so long as it survives a seasonally challenging third quarter.

As I also wrote, about June… Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

  • Although historically, June (in the past) has been a slow or weak month – I/we just saw a tremendous start (6/2) with partnership, acquisition, and regulatory news 
  • Also, ASCO opens this month with probably a lot of news flow attracting attention of funds such as hedges and electronic traders.

There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

June ‘25: understand the “flow” …

  • 7/1 – Tuesday closed positive with 21 positive, 11 negative and 3 flats
  • 6/30 - Monday closed positive with 20 positive, 11 negative and 4 flats
  • 6/27 – Friday closed negative with 10 positive, 21 negative and 4 flats
  • 6/26 - Thursday closed negative with 14 positive, 18 negative and 3 flats
  • 6/25 - Wednesday closed negative with 14 positive, 17 negative and 4 flats
  • 6/24 - Tuesday closed positive with 30 positive, 3 negative and 2 flats
  • 6/23 - Monday closed negative with 15 positive, 16 negative and 4 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • 7/1 - Tuesday: Mesoblast (MESO), Moderna (MRNA) and Lenz Therapeutics (LENZ)
  • Monday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Vericel (VCEL)
  • Friday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Mesoblast (MESO)

The worst three (3) in the session: 

  • 7/1 - Tuesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Solid Biosciences (SLDB)
  • Monday: Lenz Therapeutics (LENZ), Ionis Pharmaceuticals (IONS) and Agenus (AGEN)
  • Friday: Ultragenyx Pharmaceuticals (RARE), Moderna (MRNA) and UniQure NV (QURE)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.